|
1
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kayser G, Csanadi A, Kakanou S, Prasse A,
Kassem A, Stickeler E, Passlick B and Zur Hausen A: Downregulation
of MTSS1 expression is an independent prognosticator in squamous
cell carcinoma of the lung. Br J Cancer. 112:866–873. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peters S, Adjei AA, Gridelli C, Reck M,
Kerr K and Felip E: ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23(Suppl 7): vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li H, Zhang Y, Zhang Y, Bai X, Peng Y and
He P: TRIM31 is downregulated in non-small cell lung cancer and
serves as a potential tumor suppressor. Tumour Biol. 35:5747–5752.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee Y, Macoskay JA, Korenchukx S and
Pientay KJ: MIM, a potential metastasis suppressor gene in bladder
cancer. Neoplasia. 4:291–294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie F, Ye L, Ta M, Zhang L and Jiang WG:
MTSS1: A multifunctional protein and its role in cancer invasion
and metastasis. Front Biosci (Schol Ed). 3:621–631. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mattila PK, Salminen M, Yamashiro T and
Lappalainen P: Mouse MIM, a tissue-specific regulator of
cytoskeletal dynamics, interacts with ATP-actin monomers through
its C-terminal WH2 domain. J Biol Chem. 278:8452–8459. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mattila PK, Pykäläinen A, Saarikangas J,
Paavilainen VO, Vihinen H, Jokitalo E and Lappalainen P:
Missing-in-metastasis and IRSp53 deform PI (4,5) P2-rich membranes
by an inverse BAR domain-like mechanism. J Cell Biol. 176:953–964.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Callahan CA, Ofstad T, Horng L, Wang JK,
Zhen HH, Coulombe PA and Oro AE: MIM/BEG4, a Sonic
hedgehog-responsive gene that potentiates Gli-dependent
transcription. Genes Dev. 18:2724–2729. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma S, Guan X, Lee TK and Chan KW:
Clinicopathological significance of missing in metastasis B
expression in hepatocellular carcinoma. Hum Pathol. 38:1201–1206.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lei R, Tang J, Zhuang X, Deng R, Li G, Yu
J, Liang Y, Xiao J, Wang HY, Yang Q and Hu G: Suppression of MIM by
microRNA-182 activates RhoA and promotes breast cancer metastasis.
Oncogene. 33:1287–1296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou W, Li X, Liu F, Xiao Z, He M, Shen S
and Liu S: MiR-135a promotes growth and invasion of colorectal
cancer via metastasis suppressor 1 in vitro. Acta Biochim Biophys
Sin (Shanghai). 44:838–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mustafa N, Martin TA and Jiang WG:
Metastasis tumour suppressor-1 and the aggressiveness of prostate
cancer cells. Exp Ther Med. 2:157–162. 2011.PubMed/NCBI
|
|
15
|
Mertz KD, Pathria G, Wagner C, Saarikangas
J, Sboner A, Romanov J, Gschaider M, Lenz F, Neumann F, Schreiner
W, et al: MTSS1 is a metastasis driver in a subset of human
melanomas. Nat Commun. 5:34652014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang B, Feng P, Xiao Z and Ren EC: LIM and
SH3 protein 1 (Lasp1) is a novel p53 transcriptional target
involved in hepatocellular carcinoma. J Hepatol. 50:528–537. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang
S, Wang W, Zhang J and Zhang Y: RNAi-mediated silencing of VEGF-C
inhibits non-small cell lung cancer progression by simultaneously
down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent
axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer.
47:2353–2363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McLean GW, Carragher NO, Avizienyte E,
Evans J, Brunton VG and Frame MC: The role of focal-adhesion kinase
in cancer-a new therapeutic opportunity. Nat Rev Cancer. 5:505–515.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng B, Guo C, Guan H, Liu S and Sun MZ:
Annexin A5 as a potential marker in tumors. Clin Chim Acta.
427:42–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Huang Z, Wu S, Zang X, Liu M and
Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and
promotes osteosarcoma cell resistance to cisplatin by
down-regulating TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie F, Ye L, Chen J, Wu N, Zhang Z, Yang
Y, Zhang L and Jiang WG: The impact of Metastasis Suppressor-1,
MTSS1, on oesophageal squamous cell carcinoma and its clinical
significance. J Transl Med. 9:952011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carragher NO and Frame MC: Focal adhesion
and actin dynamics: A place where kinases and proteases meet to
promote invasion. Trends Cell Biol. 14:241–249. 2004. View Article : Google Scholar : PubMed/NCBI
|
